FDA warns Sambrosa Care that its OTC sweet dreams Night Syrup is an unapproved, misbranded drug with excessive doxylamine dosing.
What happened
FDA reviewed the product label and the product website, where Sambrosa sweet dreams Night Syrup was offered for sale as an OTC combination antihistamine and nighttime sleep-aid. The letter says the product is an unapproved new drug and is misbranded because it does not meet the OTC monograph (FDA's rules for nonprescription drugs) and has no FDA-approved application. FDA also found that the labeled directions can deliver too much doxylamine succinate and that website claims make several herbal ingredients active ingredients not allowed by the monograph.
What FDA found
The product is an unapproved new drug because no FDA-approved application is in effect and it does not meet the OTC monograph rules for legal marketing.
FD&C Act section 505(a), 21 U.S.C. 355(a); section 301(d), 21 U.S.C. 331(d)The label tells adults and children 6 and over to take 3 mL every 4 to 6 hours and up to 35 mL a day, which can give 114.1 mg of doxylamine succinate daily, above the monograph maximum of 75 mg for adults and 37.5 mg for children 6 to under 12.
OTC Monograph M012.72(d)(8)Website claims make honey, California poppy, hawthorn, hops, mistletoe, passion flower, oats, and white chestnut active ingredients, but none are recognized as acceptable active ingredients in the cold, cough, allergy monograph.
21 CFR 201.66(b)(2); OTC Monograph M012The product is also promoted as a nighttime sleep aid, but doxylamine succinate is not permitted under the nighttime sleep-aid monograph, and neither monograph allows a combination antihistamine and sleep-aid product.
OTC Monograph M010FDA says the product is misbranded because it is a nonprescription drug subject to section 505G but does not meet that section's requirements and has no approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the specific steps taken to correct the violations and prevent recurrence, or to explain why it needs more time.
Who should pay attention
- retailers and online marketplaces selling Sambrosa products
- brands selling OTC allergy or sleep-aid syrups
- companies relying on OTC monograph compliance for doxylamine products
This is a summary. Read the original letter on fda.gov.